Cardano’s weekly chart is catching the eye of technical analysts as a potential “death cross” formation emerges, raising fresh concerns about the cryptocurrency’s price direction. With the 50-week and 200-week moving averages drawing closer together, the possibility of a downward crossover in the coming weeks is sparking speculation. Should this bearish configuration play out, it would trigger a technical signal often seen as a harbinger of extended downturns across financial markets.
Cardano hits $0.148 as ‘death cross’ looms! What is the big risk for ADA investors?
A critical technical threshold
In market analysis, a “golden cross” occurs when a short-term moving average rises above a long-term one, typically seen as a bullish indicator. In contrast, the “death cross” is formed when the short-term average crosses beneath the long-term average, signaling potential weakness ahead. Right now, Cardano’s 50-week moving average is turning downward and appears poised to slip below the 200-week average in the weeks ahead, putting bears in the driver’s seat.
Glossary: A death cross is a technical indication created when a short-term moving average falls below a long-term moving average. While closely watched, it is considered a lagging indicator and does not itself establish a new price trend.
The previous weekly death cross for Cardano’s native asset ADA surfaced in December 2022, months after ADA had descended from its all-time high of nearly $3 reached in September 2021. Back then, the signal followed sustained selling pressure that had weighed on the cryptocurrency for months.
Seasoned investors view moving average crossovers as lagging indicators, so a single signal is not accepted as definitive proof of lasting trend reversals.
Downward pressure continues
Historical patterns show that ADA moved mostly sideways in the months after its last death cross, which some took as an early clue that prices were bottoming. However, analysts warn similar signals don’t guarantee identical outcomes. For example, following a golden cross in July 2025, ADA managed only a modest rally to $1.02 before renewed selling knocked the price lower.
Recently, the broad downturn in the cryptocurrency market and concerns about Cardano’s ecosystem drove ADA as low as $0.148—a level last seen in December 2020. While momentum indicators are starting to flash oversold readings, analysts say convincing evidence of a lasting recovery is still lacking.
Hoskinson’s ecosystem warning
Cardano founder Charles Hoskinson has weighed in, warning that the ongoing bear market could trigger fractures within the crypto ecosystem. After an earlier announcement that he was taking a break, Hoskinson recently clarified via video that he is not stepping away from the project.
In his video address, Charles Hoskinson said, “As an ecosystem, we stand at the edge of a cliff.”
Should Cardano repeat previous technical patterns and establish a bottom after the looming death cross, analysts believe price levels between $0.20 and $0.30 may again come into focus. On the flip side, if the current bearish trend persists, the $0.10 band could act as a major support zone.
This article originally appeared on COINTURK and tracks Cardano’s latest weekly developments as the market weighs the impact of impending technical signals and founder commentary.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Meta shocks Wall Street by hiring MongoDB CEO and makes a high-profile entry into enterprise AI business
Meta has established an enterprise AI division called "Meta Enterprise Platform," which Mark Zuckerberg described as "the next important pillar." MongoDB CEO CJ Desai has been recruited to lead it. Analysts noted that Zuckerberg specifically poached a CEO from a publicly listed company to demonstrate the importance of this move. Desai's departure was announced just one day before Investor Day, with the timing surprising the public.
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
